JP2022519301A5 - - Google Patents
Info
- Publication number
- JP2022519301A5 JP2022519301A5 JP2021545808A JP2021545808A JP2022519301A5 JP 2022519301 A5 JP2022519301 A5 JP 2022519301A5 JP 2021545808 A JP2021545808 A JP 2021545808A JP 2021545808 A JP2021545808 A JP 2021545808A JP 2022519301 A5 JP2022519301 A5 JP 2022519301A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- sulfamoyl
- trifluoromethyl
- amino
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801717P | 2019-02-06 | 2019-02-06 | |
| US62/801,717 | 2019-02-06 | ||
| PCT/IB2020/050884 WO2020161623A1 (en) | 2019-02-06 | 2020-02-04 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519301A JP2022519301A (ja) | 2022-03-22 |
| JP2022519301A5 true JP2022519301A5 (https=) | 2023-02-13 |
Family
ID=69528901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545808A Withdrawn JP2022519301A (ja) | 2019-02-06 | 2020-02-04 | Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220127247A1 (https=) |
| EP (1) | EP3921313A1 (https=) |
| JP (1) | JP2022519301A (https=) |
| CN (1) | CN113423702A (https=) |
| WO (1) | WO2020161623A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| WO2015138934A1 (en) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| KR20180029204A (ko) * | 2015-06-02 | 2018-03-20 | 애브비 에스.에이.알.엘. | 치환된 피리딘 및 사용 방법 |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
-
2020
- 2020-02-04 JP JP2021545808A patent/JP2022519301A/ja not_active Withdrawn
- 2020-02-04 CN CN202080011826.1A patent/CN113423702A/zh active Pending
- 2020-02-04 EP EP20704607.9A patent/EP3921313A1/en not_active Withdrawn
- 2020-02-04 US US17/428,353 patent/US20220127247A1/en not_active Abandoned
- 2020-02-04 WO PCT/IB2020/050884 patent/WO2020161623A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519301A5 (https=) | ||
| JP6895938B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2023027269A5 (https=) | ||
| JP3581713B2 (ja) | ホスホジエステラーゼ阻害剤としての三置換フェニル誘導体 | |
| RU2315041C2 (ru) | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения | |
| JP7365358B2 (ja) | ヒトインテグリンα４β７のアンタゴニスト | |
| JP2021504443A5 (https=) | ||
| JP2024532518A (ja) | Ｇｌｐ１ｒアゴニストとしての新規アリールエーテル置換複素環式化合物 | |
| JP2022534261A5 (https=) | ||
| JP2004532227A5 (https=) | ||
| ZA200305933B (en) | Cannabinoid receptor ligands | |
| JP2013518881A5 (https=) | ||
| JP2024518792A5 (https=) | ||
| JP2007502264A5 (https=) | ||
| CA2418868A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| JP2014532640A5 (https=) | ||
| JP2008504275A5 (https=) | ||
| JP2022552655A5 (https=) | ||
| JP2006525329A5 (https=) | ||
| JP2013505903A5 (https=) | ||
| RU2010129541A (ru) | Карбоксил- или гидроксилзамещенные производные бензимидазола | |
| JP2010501587A5 (https=) | ||
| JP2021515004A5 (https=) | ||
| HRP20140105T1 (hr) | Novi inhibitori seh i njihova upotreba | |
| JP2022543666A5 (https=) |